Effects of diabetes on myocardial capillary density and serum angiogenesis biomarkers in male rats

Clinics

Volumn 66, Issue 8, 2011, Pages 1419-1424

  Khazaei, Majid ^a   Fallahzadeh, Ali Reza ^a   Sharifi, Mohammad Reza ^a   Afsharmoghaddam, Noushin ^a   Javanmard, Shaghayegh Haghjooy ^b   Salehi, Ensieh ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Capillary Density; Diabetes; Myocardium; Nitric Oxide; Vascular Endothelial Growth Factor

Indexed keywords

BIOLOGICAL MARKER; NITRIC OXIDE; STREPTOZOCIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANIMAL; ARTICLE; BLOOD; CAPILLARY; EXPERIMENTAL DIABETES MELLITUS; HEART MUSCLE; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RAT; WISTAR RAT;

ANIMALS; BIOLOGICAL MARKERS; CAPILLARIES; DIABETES MELLITUS, EXPERIMENTAL; IMMUNOHISTOCHEMISTRY; MALE; MYOCARDIUM; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; RATS; RATS, WISTAR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; STREPTOZOCIN; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 80052775817     PISSN: 18075932     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1807-59322011000800019     Document Type: Article

References (38)

1. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-60, doi: 10.1038/nm0603-653.
2. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-18, doi: 10.1146/ annurev.med.57.121304.131306.
3. Milkiewicz M, Hudlicka O, Brown MD, Silgram H. Nitric oxide, VEGF, and VEGFR-2: interactions in activity-induced angiogenesis in rat skeletal muscle. Am J Physiol Heart Circ Physiol. 2005;289:H336-H343, doi: 10.1152/ajpheart.01105.2004.
4. Cengel A, Sahinarslan A. Nitric oxide and cardiovascular system. Anadolu Kardiyol Derg. 2006;6:364-8.
5. Tuck ML. Nitric oxide in diabetes mellitus. J Hypertens. 2003;21:1081-3, doi: 10.1097/00004872-200306000-00005.
6. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359-71, doi: 10.1038/nrm1911.
7. Hasumi Y, Mizukami H, Urabe M, Kohno T, Takeuchi K, Kume A, et al. Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. Cancer Res. 2002;62:2019-23.
8. Roberts DM, Kearney JB, Johnson JH, Rosenberg MP, Kumar R, Bautch VL. The vascular endothelial growth factor (VEGF) receptor Flt-1 (VEGFR-1) modulates Flk-1 (VEGFR-2) signaling during blood vessel formation. Am J Pathol. 2004;164:1531-5, doi: 10.1016/S0002-9440(10)63711-X.
9. Wu FT, Stefanini MO, Mac GF, Kontos CD, Annex BH, Popel AS. A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use. J Cell Mol Med. 2010;14:528-52.
10. Brem H, Tomic-Canic M. Cellular and molecular basis of wound healing in diabetes. J Clin Invest. 2007;117:1219-22, doi: 10.1172/JCI32169.
11. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27-31, doi: 10.1038/nm0195-27.
12. Movahedian A. Antihyperlipidemic effect of peucedanum pastinacifolium extract in streptozotocin-induced diabetic rats. Clinics. 2010;65:629-33.
13. Budin SB. The effects of palm oil tocotrienol-rich fraction supplementation on biochemical parameters, oxidative stress and the vascular wall of streptozotocin-induced diabetic rats. Clinics. 2009;64:235-44, doi: 10.1590/S1807-59322009000300015.
14. Carlstrom M. Angiogenesis inhibition causes hypertension and placental dysfunction in a rat model of preeclampsia. J. Hypertens. 2009;27:829-37, doi: 10.1097/HJH.0b013e328324f8ce.
15. Pratheeshkumar P. Vernolide-A inhibits tumour specific angiogenesis by regulating proinflammatory cytokines, VEGF, MMPs and TIMP. Eur J Pharmacol. 2011;656:10-8, doi: 10.1016/j.ejphar.2010.12.041.
16. Nematbakhsh M. The effect of estrogen on serum nitric oxide concentrations in normotensive and DOCA Salt hypertensive ovariectomized rats. Clin Chim Acta. 2004;344:53-7, doi: 10.1016/j.cccn.2004.01.019.
17. Li P. Role of bradykinin, nitric oxide, and angiotensin II type 2 receptor in imidapril-induced angiogenesis. Hypertension. 2008;51:252-58, doi: 10.1161/HYPERTENSIONAHA.107.097394.
18. Cooke JP. NO and angiogenesis. Atheroscler Suppl. 2003;4:53-60, doi: 10.1016/S1567-5688(03)00034-5.
19. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol. 1998;274(3 Pt 2):H1054-H1058.
20. Zhao X, Lu X, Feng Q. Deficiency in endothelial nitric oxide synthase impairs myocardial angiogenesis. Am J Physiol Heart Circ Physiol. 2002;283:H2371-H2378.
21. Lash JM, Nase GP, Bohlen HG. Acute hyperglycemia depresses arteriolar NO formation in skeletal muscle. Am J Physiol. 1999;277:H1513-H1520.
22. Brodsky SV, Morrishow AM, Dharia N, Gross SS, Goligorsky MS. Glucose scavenging of nitric oxide. Am J Physiol Renal Physiol. 2001;280:F480-F486.
23. Bohlen HG, Nase GP. Arteriolar nitric oxide concentration is decreased during hyperglycemia-induced betaII PKC activation. Am J Physiol Heart Circ Physiol. 2001;280:H621-H627.
24. Silva AM, Penno Lde M, Bertoluci MC, Irigoyen MC, Schaan BD. Insulin therapy does not interfere with venous endothelial function evaluation in patients with type 2 diabetes mellitus. Clinics. 2010;65:1139-42, doi: 10.1590/S1807-59322010001100015.
25. Ding Y, Vaziri ND, Coulson R, Kamanna VS, Roh DD. Effects of simulated hyperglycemia, insulin, and glucagon on endothelial nitric oxide synthase expression. Am J Physiol Endocrinol Metab. 2000;279:E11-E17.
26. Bagi Z, Toth E, Koller A, Kaley G. Microvascular dysfunction after transient high glucose is caused by superoxide-dependent reduction in the bioavailability of NO and BH(4). Am J Physiol Heart Circ Physiol. 2004;287:H626-H633, doi: 10.1152/ajpheart.00074.2004.
27. Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci (Lond). 2002;102:187-94, doi: 10.1042/CS20010178.
28. Li Y, Hazarika S, Xie D, Pippen AM, Kontos CD, Annex BH. In mice with type 2 diabetes, a vascular endothelial growth factor (VEGF)-activating transcription factor modulates VEGF signaling and induces therapeutic angiogenesis after hindlimb ischemia. Diabetes. 2007;56:656-65, doi: 10.2337/db06-0999.
29. Sasso FC, Torella D, Carbonara O, Ellison GM, Torella M, Scardone M, et al. Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol. 2005;46:827-34, doi: 10.1016/j.jacc.2005.06.007.
30. Chou E, Suzuma I, Way KJ, Opland D, Clermont AC, Naruse K, et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue. Circulation. 2002;105:373-9, doi: 10.1161/hc0302.102143.
31. Gao L, Yu DM. Molecular mechanism of limbs' postischemic revascularization improved by perindopril in diabetic rats. Chin Med J (Engl). 2008;121:2129-33.
32. Kivela R, Silvennoinen M, Lehti M, Jalava S, Vihko V, Kainulainen H. Exercise-induced expression of angiogenic growth factors in skeletal muscle and in capillaries of healthy and diabetic mice. Cardiovasc Diabetol. 2008;7:13, doi: 10.1186/1475-2840-7-13.
33. Larger E, Marre M, Corvol P, Gasc JM. Hyperglycemia-induced defects in angiogenesis in the chicken chorioallantoic membrane model. Diabetes. 2004;53:752-61, doi: 10.2337/diabetes.53.3.752.
34. Waltenberger J. VEGF resistance as a molecular basis to explain the angiogenesis paradox in diabetes mellitus. Biochem Soc Trans. 2009;37:1167-70.
35. Hazarika S, Dokun AO, Li Y, Popel AS, Kontos CD, Annex BH. Impaired angiogenesis after hindlimb ischemia in type 2 diabetes mellitus: differential regulation of vascular endothelial growth factor receptor 1 and soluble vascular endothelial growth factor receptor 1. Circ Res. 2007;101:948-56, doi: 10.1161/CIRCRESAHA.107.160630.
36. Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443:993-7, doi: 10.1038/nature05249.
37. Chang YT, Chang MC, Wei SC, Tien YW, Hsu C, Liang PC, et al. Serum vascular endothelial growth factor/soluble vascular endothelial growth factor receptor 1 ratio is an independent prognostic marker in pancreatic cancer. Pancreas. 2008;37:145-50, doi: 10.1097/MPA.0b013e318164548a.
38. Bando H, Weich HA, Brokelmann M, Horiguchi S, Funata N, Ogawa T, et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer. 2005;92:553-61.